1 March 2025 false No description of principal activity Taxfiler 2024.6 NI709560business:PrivateLimitedCompanyLtd2025-03-012026-02-28 NI7095602025-02-28 NI7095602025-03-012026-02-28 NI709560business:AuditExemptWithAccountantsReport2025-03-012026-02-28 NI709560business:FilletedAccounts2025-03-012026-02-28 NI7095602026-02-28 NI709560business:Director12025-03-012026-02-28 NI709560business:Director22025-03-012026-02-28 NI709560business:Director32025-03-012026-02-28 NI709560business:RegisteredOffice2025-03-012026-02-28 NI7095602025-02-28 NI709560core:WithinOneYear2026-02-28 NI709560core:WithinOneYear2025-02-28 NI709560core:ShareCapitalcore:PreviouslyStatedAmount2026-02-28 NI709560core:ShareCapitalcore:PreviouslyStatedAmount2025-02-28 NI709560core:SharePremiumcore:PreviouslyStatedAmount2026-02-28 NI709560core:SharePremiumcore:PreviouslyStatedAmount2025-02-28 NI709560core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2026-02-28 NI709560core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-02-28 NI709560core:PreviouslyStatedAmount2026-02-28 NI709560core:PreviouslyStatedAmount2025-02-28 NI709560business:SmallEntities2025-03-012026-02-28 NI709560countries:NorthernIreland2025-03-012026-02-28 NI709560core:FurnitureFittings2025-03-012026-02-28 NI709560core:ComputerEquipment2025-03-012026-02-28 NI709560core:FurnitureFittings2025-02-28 NI709560core:ComputerEquipment2025-02-28 NI709560core:FurnitureFittings2026-02-28 NI709560core:ComputerEquipment2026-02-28 NI7095602024-02-012025-02-28 iso4217:GBP xbrli:pure
Company Registration No. NI709560 (Northern Ireland)
Antigenesis Biologics Ltd Unaudited accounts for the year ended 28 February 2026
Antigenesis Biologics Ltd Unaudited accounts Contents
Page
- 2 -
Antigenesis Biologics Ltd Company Information for the year ended 28 February 2026
Directors
Mr Terence Hugh Brannigan Dr Ciaran Patrick Anthony Doherty Dr Hugh Patrick Morgan
Company Number
NI709560 (Northern Ireland)
Registered Office
78 Teconnaught Road Crossgar Downpatrick County Down BT30 9HH Northern Ireland
Accountants
Nuvem 9 Ltd The Mount Business Centre Woodstock Link Belfast County Antrim BT6 8DD
- 3 -
Antigenesis Biologics Ltd Statement of financial position as at 28 February 2026
2026 
2025 
Notes
£ 
£ 
Fixed assets
Tangible assets
18,176 
23,012 
Current assets
Debtors
27,848 
20,980 
Cash at bank and in hand
179,262 
31,350 
207,110 
52,330 
Creditors: amounts falling due within one year
(126,459)
(9,255)
Net current assets
80,651 
43,075 
Net assets
98,827 
66,087 
Capital and reserves
Called up share capital
10 
10 
Share premium
50,000 
50,000 
Profit and loss account
48,817 
16,077 
Shareholders' funds
98,827 
66,087 
For the year ending 28 February 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 16 September 2026 and were signed on its behalf by
Dr Hugh Patrick Morgan Director Company Registration No. NI709560
- 4 -
Antigenesis Biologics Ltd Notes to the Accounts for the year ended 28 February 2026
1
Statutory information
Antigenesis Biologics Ltd is a private company, limited by shares, registered in Northern Ireland, registration number NI709560. The registered office is 78 Teconnaught Road, Crossgar, Downpatrick, County Down, BT30 9HH, Northern Ireland.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
5 year straight line
Computer equipment
3 year straight line
4
Tangible fixed assets
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 March 2025
20,847 
2,757 
23,604 
Additions
- 
355 
355 
At 28 February 2026
20,847 
3,112 
23,959 
Depreciation
At 1 March 2025
263 
329 
592 
Charge for the year
4,169 
1,022 
5,191 
At 28 February 2026
4,432 
1,351 
5,783 
Net book value
At 28 February 2026
16,415 
1,761 
18,176 
At 28 February 2025
20,584 
2,428 
23,012 
- 5 -
Antigenesis Biologics Ltd Notes to the Accounts for the year ended 28 February 2026
5
Debtors
2026 
2025 
£ 
£ 
Amounts falling due within one year
VAT
3,758 
13,007 
Trade debtors
- 
1,500 
Accrued income and prepayments
4,607 
6,463 
Other debtors
19,483 
10 
27,848 
20,980 
6
Creditors: amounts falling due within one year
2026 
2025 
£ 
£ 
Trade creditors
- 
6,216 
Taxes and social security
1,094 
1,039 
Other creditors
120,000 
- 
Loans from directors
577 
- 
Accruals
4,788 
2,000 
126,459 
9,255 
7
Average number of employees
During the year the average number of employees was 2 (2025: 2).
- 6 -